Skip to main content
TipRanks
Go Ultimate75% OFF

AxoGen (AXGN) AI Stock Analysis

509 Followers
AXGN

AxoGen

(NASDAQ:AXGN)

Select Model
Rating:68Neutral
Price Target:$64.00â–²(15.57% Upside)
Action:downgraded
Date:11/12/26

AXGN scores well on improving fundamentals and cash flow, plus a clearly bullish price trend and a strong, guidance-raising earnings update. The overall score is held back primarily by weak valuation signals tied to ongoing profitability limitations (negative P/E) and some near-term margin/cost and integration risks highlighted on the call.

Positive Factors
Revenue Growth and Gross MarginsStrong revenue growth alongside consistently high gross margins indicates attractive product economics and expanding adoption of AxoGen’s peripheral nerve repair portfolio. These characteristics can support reinvestment, commercial expansion, and improving operating leverage as sales scale over the next several quarters.
Negative Factors
Persistent UnprofitabilityAxoGen has not yet converted strong revenue growth and gross margins into durable GAAP profitability. Continued operating losses constrain retained capital, leave the company dependent on further scale improvements, and make sustained expense discipline essential for long-term earnings conversion.

AxoGen (AXGN) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%150%AXGN+119.24%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$3.31B
Dividend Yield
―
Average Volume (3M)
1.55M
Price to Earnings (P/E)
-85.5
Beta (1Y)
1.19
Revenue Growth
24.32%
EPS Growth
-1274.47%
Country
US
Employees
622
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

AxoGen Business Overview & Revenue Model

Company Description

AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance...

How the Company Makes Money

AxoGen primarily makes money by selling peripheral nerve repair products to hospitals, ambulatory surgery centers, and other healthcare providers for use in surgical procedures. Revenue is generated from product sales across its portfolio, which incl...

AxoGen Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:47.84%|Next Earnings Date:Feb 23, 2027
Earnings Call SentimentPositive

The call was strongly positive, supported by 26.2% year-over-year revenue growth, accelerating breast performance, improved adjusted profitability, expanded payer coverage, clinical-study progress, completion of the BioCircuit acquisition, and raised full-year revenue guidance. The principal challenges were lower year-over-year gross margin, expected fourth-quarter margin pressure, higher operating and acquisition-related costs, Aetna's utilization-management restriction, and future amortization and integration considerations. Highlights significantly outweighed lowlights.

Positive Updates

Strong Third-Quarter Revenue Growth
Third-quarter revenue was $75.8 million, up 26.2% year-over-year, with growth in all markets. Breast revenue grew more than 50% year-over-year, while extremities, OMF, and head and neck combined grew 10.7%.

Negative Updates

Year-Over-Year Gross Margin Decline
Third-quarter gross margin was 74.8%, down from 76.6% a year ago, although it increased from 72.7% in the second quarter. Lindsey Hartley said gross margin declined year-over-year because product costs were 3% higher, partially offset by 1.2% lower write-offs.

Company Guidance

For full-year 2026, Axogen now expects revenue growth of at least 29% or revenue of at least $290 million, including at least $7 million of revenue from BioCircuit; excluding BioCircuit, organic revenue is expected to be at least $283 million, representing organic growth of at least 26%, with gross margin of at least 73% and positive free cash flow. The guidance does not assume material benefit from payer coverage decisions beyond what's already known or from prostate market development, and BioCircuit revenue guidance contemplates some level of integration or disruption risk; the purchase-accounting inventory step-up could negatively impact gross margin in the fourth quarter and for the full year relative to current expectations. Gross margin is expected to decline in the fourth quarter sequentially and to be slightly less than the second quarter. Full-year 2027 is expected to be more in line with full-year 2026, with formal 2027 guidance in the first quarter; the $34 million of NerveTape sales next year is incremental and net of cannibalization. Prostate is not included in current or long-range guidance, and extremities are expected to range from very high single digit to low double-digit growth quarter-to-quarter, year in, year out.

AxoGen Financial Statement Overview

Summary

Revenue is accelerating (to $266.9M TTM) with strong gross margins (~74–82%) and a notable improvement in cash generation (TTM operating cash flow $28.4M; free cash flow $22.0M). The main drag is still profitability: net income remains negative in TTM with negative ROE, indicating the business has not yet converted growth into durable earnings.

Income Statement

56Neutral

Balance Sheet

72Positive

Cash Flow

78Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue266.93M225.21M187.34M159.01M138.58M127.36M
Gross Profit198.00M167.35M141.98M121.87M108.81M104.43M
EBITDA-21.24M192.00K6.08M-13.33M-23.47M-20.89M
Net Income-31.92M-15.70M-9.96M-21.72M-28.95M-26.98M
Balance Sheet
Total Assets550.34M221.69M203.73M196.83M195.39M208.02M
Cash, Cash Equivalents and Short-Term Investments348.07M35.55M33.48M31.02M48.79M84.09M
Total Debt19.47M67.63M68.69M69.29M67.43M67.45M
Total Liabilities54.24M92.84M99.82M101.16M94.39M95.47M
Stockholders Equity496.10M128.85M103.91M95.67M101.00M112.55M
Cash Flow
Free Cash Flow16.31M-2.93M11.00K-20.63M-37.32M-41.80M
Operating Cash Flow22.63M812.00K4.54M-5.72M-16.07M-13.40M
Investing Cash Flow-22.36M-5.32M-10.30M19.25M-3.20M-23.65M
Financing Cash Flow293.55M10.50M2.29M1.95M1.79M20.45M

AxoGen Technical Analysis

Technical Analysis SentimentPositive
Last Price55.38

Price Trends

50DMA43.41Positive
100DMA44.30Positive
200DMA40.63Positive

Market Momentum

MACD4.04Negative
RSI68.27Neutral
STOCH65.84Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AXGN, the sentiment is Positive. The current price of 55.38 is above the 20-day moving average (MA) of 47.37, above the 50-day MA of 43.41, and above the 200-day MA of 40.63, indicating a bullish trend. The MACD of 4.04 indicates Negative momentum. The RSI at 68.27 is Neutral, neither overbought nor oversold. The STOCH value of 65.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AXGN.

AxoGen Risk Analysis

AxoGen disclosed 60 risk factors in its most recent earnings report. AxoGen reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.If our estimates of the TAM for peripheral nerve repair and reconstruction are inaccurate, our growth prospects and financial performance could be materially adversely affected.Q4, 2025
2.We obtained regulatory approval for certain uses of Avance through the FDA's accelerated approval pathway and traditional approval will be contingent on successful completion of a confirmatory post-approval trial. Failure to successfully complete our confirmatory post-approval trial or obtain traditional approval would have a material adverse effect on our business.Q4, 2025
3.The manufacturing process for Avance is complex and we or our third-party contractors may encounter difficulties in production. If we or our third-party contractors encounter such difficulties, our ability to supply Avance for commercial sale could be delayed or halted entirely, which would have a material adverse effect on our business.Q4, 2025

AxoGen Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AXGN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AXGNAXGN68Neutral$3.31B-85.46-11.34%―24.32%-1274.47%
BVSBVS66Neutral$881.37M12.3527.23%―3.87%623.68%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
OFIXOFIX44Neutral$277.17M-6.14-10.32%―2.12%63.59%
TELATELA43Neutral$34.42M-1.05425.91%―1.46%15.79%
IARTIART40Underperform$1.09B84.361.24%―0.84%―
XTNTXTNT39Underperform$29.43M-2.23-36.21%―-24.44%-1012.80%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%AXGNIARTOFIXXTNTTELABVSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AXGN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AXGNAxoGen55.3831.37130.65%
IARTIntegra Lifesciences13.982.5622.42%
OFIXOrthofix Medical Inc.6.80-7.60-52.78%
XTNTXtant Medical Holdings Inc0.21-0.44-67.60%
TELATela Bio, Inc.0.76-0.42-35.51%
BVSBioventus, Inc.10.463.4749.64%

AxoGen Corporate Events

Business Operations and Strategy

AxoGen Highlights Prostate Nerve Reconstruction Opportunity and Clinical Results

Positive
Nov 9, 2026

On November 9, 2026, Axogen posted a corporate presentation outlining its prostate nerve reconstruction opportunity. The presentation described an estimated $754 million total addressable market tied to about 110,000 annual robotic-assisted prostatec...

Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and Financing

AxoGen Raises Outlook on Strong Q3 2026 Results

Positive
Oct 28, 2026

AxoGen Inc., a U.S.-based leader in peripheral nerve repair technologies, markets a portfolio of nerve grafts, connectors, protectors, soft tissue matrices, and NerveTape aimed at restoring motor and sensory function following traumatic or surgical n...

Business Operations and StrategyFinancial DisclosuresM&A TransactionsProduct-Related Announcements

AxoGen Acquires BioCircuit, Expands Peripheral Nerve Portfolio

Positive
Oct 1, 2026

On October 1, 2026, AxoGen completed its acquisition of privately held BioCircuit Technologies, adding NerveTape, the first FDA-cleared sutureless device for repairing transected peripheral nerves, to its product lineup. Management framed the transac...

Business Operations and StrategyM&A TransactionsPrivate Placements and Financing

AxoGen to Acquire BioCircuit, Expanding Nerve Repair Portfolio

Positive
Sep 10, 2026

On September 9–10, 2026, Axogen agreed to acquire BioCircuit Technologies for $200 million in cash, with BioCircuit to become a wholly owned subsidiary after a spin‑out of its unrelated electronics business. The deal, expected to close in the fourth...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 12, 2026